Next gathering is already ahead: PTCOG 65 in Bangkok, Thailand, 7-12 June 2027! The global particle therapy community will come together once again in a region where the field is rapidly expanding and gaining momentum. 🔗 bit.ly/4xrlhXe #PTCOG65 #ParticleTherapy

I deeply believe that we need biology to guide the development of the radiotherapy technologies. With emerging immunotherapy and molecular targeted treatments, we need to develop more precise and effective local therapy. More importantly, we should develop clinical, biology and image AI-guided individualized radiotherapy to work together with novel systemic therapy.

So glad to see our young investigators to be recognized in #PTCOG64. They play a crucial role in developing/optimizing particle technologies.

I am honored to receive this recognition. I thank PTCOG for the opportunity to serve. Congratulations to Dr. Hug for his outstanding achievements. We should continue to optimize the photon/proton technologies and should never stop exploring novel ways to treat our patients.

What is the future of particle therapy? Will we see better imaging, adaptive auto-plan optimization, and multi-ion therapy? I believe that we will never achieve a single “best beam” and will always need a “better” beam, utilizing biological and physical optimization along with image guidance. Radiotherapy is akin to satellite-guided missiles; there is always room for improvement in accuracy and effectiveness. Different ion has unique biological and physical features that can be used to tailor the “beam” to particular lesion. We are looking forward to the development of cost-effective, biology- and physics-based multi-ion systems in the near future.@PTCOG_Official

It has been my great pleasure and honor to serve as the Scientific Program Co-Chair and Clinical Leading Chair for PTCOG for the past four years. I am delighted to witness the advancement of cutting-edge radiation therapy technology and the growth of our talented young colleagues. This will be my last time presenting the Dr. Michael Goitein Award to our outstanding clinical young investigator. @BrianDeMD @PTCOG_Official

In head and neck cancer, two randomized studies comparing IMRT and IMPT (proton TX) were published in Lancet this year. #PTCOG64. Both studies showed improvements in some acute side effects, and one study found overall survival benefits favoring IMPT. The controversial issue is how much better clinical outcomes need to be to justify the cost of IMPT. If you were a patient, would you want IMPT? @PTCOG_Official @SJFrankMD

Today's plenary session of #PTCOG64 Day 2 focused on the immunological mechanisms and potential advantages of particle therapy and flash therapy. These approaches may spare lymphocytes, function as in situ vaccines, and modify the microenvironment when combined with immunotherapy, offering greater potential for the future. @PTCOG_Official

The variable Relative Biological Effectiveness (RBE) and Linear Energy Transfer (LET) in particle therapy can present both advantages and disadvantages for tumor control and side effects; thus, optimization is crucial. @PTCOG_Official

PTCOG 64 opening ceremony is happening right now in Deauville, France.#PTCOG @PTCOG_Official

I just realized that this is Jose who was trained with us in MDACC 15 years ago! So happy to see him again!

The XXIII National Congress #SEOR2026 has concluded with a fantastic party. I did not realize that President @drjavierserrano @SEOR_ES is not only an outstanding radiation oncologist but also a fantastic guitarist. Music is in the blood of Spain. The people here are so lovely, beautiful, kind, and talented. I love this country!

I am honored to be invited to give a plenary presentation at the XXIII National Congress #SEOR2026, which is being held today in the beautiful city of Alicante, Spain. The meeting is well organized by Dr. @drjavierserrano @SEOR_ESP and the food is amazing!

Can 3 Gy help osteoarthritis pain? In this US retrospective series, LDRT 0.5 Gy x 6 improved mean Numeric Rating Scale pain scores from 7.3 to 2.6 at ~12 weeks, with 79% achieving a clinically meaningful ≥2-point reduction. Low burden. Noninvasive. Interesting signal for selected patients with persistent OA pain. #OncTwitter #RadOnc

For sure, we need to know more about the brain, the anatomy, functions and dose response for each specific structure. Patients survive longer, have more recurrence over years or decades and brain metastasis becomes more complex now.

When I was a resident 24 years ago, we were taught that renal cancer is radiation resistant disease. Now, we learn that RT can achieve up to 100% local control when RT dose is appropriate.

Histology matters and SABR dose matters.

A heartfelt thank you to our outstanding chairs, Drs. @StephenVLiu and Tina Cascone, and to every single faculty member, attendee, and sponsor who helped make #TexasLung26 such a success. This year’s conference was truly our best yet, packed with meaningful discussions, wonderful energy from start to finish, and a shared passion to improve care and outcomes for patients. SAVE THE DATE: April 8-10, 2027 in Austin, TX! ow.ly/Ybto50YP94A Here’s a highlight video capturing the magic 🫁 @dapattmd @karenkellymd @christine_lovly

El XXIII Congreso Nacional #SEOR2026 contaremos con la participación del Prof. @JoeChangMD en la sesión magistral: Evidence for SBRT and Proton Therapy in Lung Cancer. Alicante | 📅 3–5 junio 2026 congresoseor.es/seor2026 #SEOR2026 #OncologíaRadioterápica #Protonterapia

More than 1/3 of our clinical practice is re-RT. The challenges include how to precisely calculate composite biological effective dose and time-dependent repair factor for each organ。